Delayed clinical trial data delivery is a growing problem for pharmaceutical companies and one that can have catastrophic consequences for the development of their promising pipeline candid
In the US, fewer than three per cent of eligible patients participate in clinical trials – a figure that drops drastically when applied to ethnic minorities living in underserved communities.
If clinical trial results were more quickly and openly accessible, medical improvements would be implemented more swiftly too. So what can be done to ease this process?
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh